Calliditas Therapeutics: Funding, Investors & Team (Sep 2026)
Calliditas Therapeutics AB, a pharmaceutical company in Stockholm, Sweden, specializes in developing high-quality pharmaceutical products for patients with limited treatment options in specific medical conditions. The company aims to contribute to the marketing efforts either partially or fully. Their main focus is on the development and commercialization of a unique product called Nefecon. Nefecon is a two-step formulation that combines a delayed release of the active substance budesonide with a concentrated release in a specific target area. This patented formulation is designed to treat patients with inflammatory renal disease known as IgA nephropathy (IgAN). Calliditas is currently conducting a Phase 3 study on a global scale for IgAN and plans to market Nefecon in the United States.
Calliditas Therapeutics has raised $102M across 1 funding round on record, the most recent an undisclosed round of $102M announced in Dec 2023.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Calliditas Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2023.
Calliditas Therapeutics Funding Rounds
Calliditas Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Calliditas Therapeutics Funding Compared to Other Biotechnology Startups
Calliditas Therapeutics' latest round of $102M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Calliditas Therapeutics in Biotechnology and Stockholm
Companies Similar to Calliditas Therapeutics
Pixelgen Technologies, established in Sweden in 2020, focuses on the advancement of biomedical research and…
Oblique Therapeutics is developing a new type of antibody-based medication for chronic pain and metastatic…
Emulsi Biotech is a biotechnology company that develops lipid technology to deliver biologic drugs orally.
Our vision is to develop and bring to the market safe and effective treatments for women specific diseases…
OncoZenge is a Swedish pharmaceutical company. It develops better products for the supportive care of cancer…
Elicera Therapeutics is a clinical stage immuno-oncology company developing cell and gene therapies for…
Alligator Bioscience is an innovative research based biotech company focused on developing novel drugs for…
Moleculent is dedicated to creating tech-based products that utilize fresh knowledge about the molecular…
Bio-Works was established in 2006 and specializes in creating, producing, and distributing cutting-edge…
Verigraft AB is a biotech company that creates personalized tissue-engineered transplants for use in…
Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic…
ArgusEye is a biotech firm that offers sensor solutions for instant identification of biological systems and…
Calliditas Therapeutics Funding FAQs
What does Calliditas Therapeutics do?
Calliditas Therapeutics AB, a pharmaceutical company in Stockholm, Sweden, specializes in developing high-quality pharmaceutical products for patients with limited treatment options in specific medical conditions. The company aims to contribute to the marketing efforts either partially or fully. Their main focus is on the development and commercialization of a unique product called Nefecon. Nefecon is a two-step formulation that combines a delayed release of the active substance budesonide with a concentrated release in a specific target area. This patented formulation is designed to treat patients with inflammatory renal disease known as IgA nephropathy (IgAN). Calliditas is currently conducting a Phase 3 study on a global scale for IgAN and plans to market Nefecon in the United States.
How much funding has Calliditas Therapeutics raised?
Calliditas Therapeutics has raised $102M across 1 round on record. The most recent is an undisclosed round of $102M announced in Dec 2023.
When did Calliditas Therapeutics last raise funding?
Calliditas Therapeutics' most recent funding round on record is an undisclosed round of $102M, announced in Dec 2023.
Who founded Calliditas Therapeutics?
FundedIQ lists Mikael Bender (Founder) at Calliditas Therapeutics.
Where is Calliditas Therapeutics headquartered?
Calliditas Therapeutics is based in Stockholm, Stockholms Lan, Sweden.
How many employees does Calliditas Therapeutics have?
Calliditas Therapeutics is in the 101-250 employee band.
How does Calliditas Therapeutics' funding compare to other Biotechnology startups?
Calliditas Therapeutics' latest round of $102M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Calliditas Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Calliditas Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.